BMJ Open

Bowel dysfunction after rectal cancer treatment: a study comparing the specialist’s versus patient’s perspective

Tina Yen-Ting Chen, Katrine Jøssing Emmertsen, Søren Laurberg

ABSTRACT

Objectives: To investigate how bowel dysfunction after sphincter-preserving rectal cancer treatment, known as low anterior resection syndrome (LARS), is perceived by rectal cancer specialists, in relation to the patient’s experience.

Design: Questionnaire study.

Setting: International.

Participants: 58 rectal cancer specialists (45 colorectal surgeons and 13 radiation oncologists).

Research procedure: The Low Anterior Resection Syndrome Score (LARS score) is a five-item instrument for evaluation of LARS, which was developed from and validated on 961 patients. The 58 specialists individually completed two LARS score-based exercises. In Exercise 1, they were asked to select, from a list of bowel dysfunction issues, five items that they considered to disturb patients the most. In Exercise 2, they were given a list of scores to assign to the LARS score items, according to the impact on quality of life (QOL).

Outcome measures: In Exercise 1, the frequency of selection of each issue, particularly the five items included in the LARS score, was compared with the frequency of being selected at random. In Exercise 2, the answers were compared with the original patient-derived scores.

Results: Four of the five LARS score issues had the highest frequencies of selection (urgency, clustering, incontinence for liquid stool and frequency of bowel movements), which were also higher than random. However, the remaining LARS score issue (incontinence for flatus) showed a lower frequency than random. Scores assigned by the specialists were significantly different from the patient-derived scores (p<0.01). The specialists grossly overestimated the impact of incontinence for liquid stool and frequent bowel movements on QOL, while they markedly underestimated the impact of clustering and urgency. The results did not differ between surgeons and oncologists.

Conclusions: Rectal cancer specialists do not have a thorough understanding of which bowel dysfunction symptoms truly matter to the patient, nor how these symptoms affect QOL.

INTRODUCTION

In the past few decades, one of the most notable advancements in colorectal surgery has been the increasing use of sphincter-preserving procedures with a low colorectal or colocolonic anastomosis.1 Such surgery avoids permanent colostomy, and has become the standard treatment for mid and low rectal cancers.2 However, many patients experience bothersome changes in bowel habits after the surgery, especially when it is combined with radiotherapy. These changes include faecal incontinence, frequent bowel movements, urgency and emptying difficulties. The complex of symptoms is referred to as ‘low anterior resection syndrome’ (LARS). LARS has been reported to affect up to 60–90% of patients who undergo low or ultralow anterior resection,3–6 and often compromises quality of life (QOL).7–10

Given the prevalence and impact on QOL of LARS, treating doctors should have an accurate understanding of the syndrome, so that patients can be adequately informed prior to treatment, as well as appropriately monitored and managed post-treatment. More importantly, doctors should have a good appreciation of how the patient views and experiences LARS, so that the information and care provided actually make a difference to the patient.

Our research group has devised the Low Anterior Resection Syndrome Score (LARS score), a concise scoring instrument for evaluation of bowel function after sphincter-preserv
preserving procedures with or without radiotherapy for rectal cancer. The content and scoring algorithm of the LARS score are shown in figure 1. The instrument has been developed from and validated on a nationwide cohort of 961 Danish patients, who received curative low anterior resection with or without radiotherapy for non-disseminated rectal cancer in Denmark between 2001 and 2007. The score has been designed to reflect the severity of bowel dysfunction symptoms and the impact on QOL. In addition to the original Danish version, the LARS score has been translated into several other languages (English, Dutch, Swedish, Spanish and German: validation is in progress for the former two, and the latter three have been validated in an international setting). Furthermore, we have recently observed an association between the LARS score and many of the scales of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Module (EORTC QLQ-C30).

The aim of this study was to investigate the rectal cancer specialist’s awareness of the patient’s experience of LARS, using the LARS score.

**METHODS**

**Recruitment of specialists**

Top specialist colorectal surgeons and radiation oncologists were approached at five European colorectal conferences in May and June 2012 (by author SL). These specialists were primarily keynote speakers, moderators or faculty members of the conference. They were first invited to participate in the study, and were then asked to nominate a colleague of the opposite specialty (a surgeon was asked to

---

**LARS-score - Scoring Instructions**

Add the scores from each 5 answers to one final score.

<table>
<thead>
<tr>
<th>Question</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you ever have occasions when you cannot control your flatus (wind)?</td>
<td></td>
</tr>
<tr>
<td>☐ No, never</td>
<td>0</td>
</tr>
<tr>
<td>☐ Yes, less than once per week</td>
<td>4</td>
</tr>
<tr>
<td>☐ Yes, at least once per week</td>
<td>7</td>
</tr>
<tr>
<td>Do you ever have any accidental leakage of liquid stool?</td>
<td></td>
</tr>
<tr>
<td>☐ No, never</td>
<td>0</td>
</tr>
<tr>
<td>☐ Yes, less than once per week</td>
<td>3</td>
</tr>
<tr>
<td>☐ Yes, at least once per week</td>
<td>3</td>
</tr>
<tr>
<td>How often do you open your bowels?</td>
<td></td>
</tr>
<tr>
<td>☐ More than 7 times per day (24 hours)</td>
<td>4</td>
</tr>
<tr>
<td>☐ 4-7 times per day (24 hours)</td>
<td>2</td>
</tr>
<tr>
<td>☐ 1-3 times per day (24 hours)</td>
<td>0</td>
</tr>
<tr>
<td>☐ Less than once per day (24 hours)</td>
<td>5</td>
</tr>
<tr>
<td>Do you ever have to open your bowels again within one hour of the last bowel opening?</td>
<td></td>
</tr>
<tr>
<td>☐ No, never</td>
<td>0</td>
</tr>
<tr>
<td>☐ Yes, less than once per week</td>
<td>9</td>
</tr>
<tr>
<td>☐ Yes, at least once per week</td>
<td>11</td>
</tr>
<tr>
<td>Do you ever have such a strong urge to open your bowels that you have to rush to the toilet?</td>
<td></td>
</tr>
<tr>
<td>☐ No, never</td>
<td>0</td>
</tr>
<tr>
<td>☐ Yes, less than once per week</td>
<td>11</td>
</tr>
<tr>
<td>☐ Yes, at least once per week</td>
<td>16</td>
</tr>
</tbody>
</table>

**Total Score:**

<table>
<thead>
<tr>
<th>Interpretation</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>0-20:</td>
<td>No LARS</td>
</tr>
<tr>
<td>21-29:</td>
<td>Minor LARS</td>
</tr>
<tr>
<td>30-42:</td>
<td>Major LARS</td>
</tr>
</tbody>
</table>

*Figure 1* The Low Anterior Resection Syndrome Score (LARS score).
nominate an oncologist and vice versa), whom they usually work the closest with in managing rectal cancer. The nominated specialists were subsequently sent an email invitation in July and August 2012 to take part in the study.

Once a specialist agreed to participate, confirmation was sought regarding whether the specialist had seen the LARS score previously. A specialist was only eligible to take part if he or she had not seen the LARS score before. In addition, colorectal surgeons were asked to indicate whether they deal with functional bowel disorders on a regular basis.

Each specialist then proceeded to complete two exercises, as detailed below.

**Data collection**

**Exercise 1**

The LARS score consists of five questions, which were selected from a pool of items extracted from the existing bowel function assessment instruments and the current literature. By applying binomial regression on the response to these items obtained from half of the aforementioned cohort of Danish patients, the five questions (with at least one question representing each of the four known LARS symptom categories, namely incontinence, frequency, urgency and emptying difficulties) showing the highest prevalence and impact on QOL were identified.

The purpose of Exercise 1 was to examine how well the specialist could recognise issues that patients find the most bothersome out of the range of LARS symptomatology. In this exercise, the specialist was presented with a list of 17 bowel dysfunction issues corresponding to the items in the original pool, along with a brief explanation similar to the one given above of how the five LARS score questions were chosen from this pool. The specialist was then asked to pick the five that he or she thought were selected for the LARS score.

**Exercise 2**

The score value of each response option of the LARS score questions indicates the extent to which it affects QOL. The higher the value, the higher the impact on QOL. The value is a derivative of the relative risk that the response option yielded in the binomial regression analysis.

The purpose of Exercise 2 was to explore how well the specialist could estimate the degree of impact certain LARS symptoms pose on the patient’s QOL. In this exercise, the specialist was presented with all the five LARS score questions and the 16 associated response options, where only the zero scores were shown. The specialist was also presented with a list of the 11 non-zero score values in ascending order, and a brief explanation similar to the one given above of how these values were established. The specialist was then asked to assign each score on the list to a response option that he or she deemed the most fitting.

**Mode of exercise completion**

Participating specialists completed the exercises individually, in sequential order (Exercise 1 followed by Exercise 2, where Exercise 2 was not revealed until Exercise 1 was completed), and in one of two ways. Those recruited at the conferences completed the exercises on paper, administered by one of the authors (SL) in person. Those recruited via email completed the exercises electronically, administered by one of the authors (TY-TC) via an internet teleconferencing session. All the materials were presented in English.

**Statistical analysis**

**Exercise 1**

For each of the 17 bowel dysfunction issues, the frequency of being selected by the specialists was calculated and compared with the expected frequency of being chosen if the specialists picked randomly. The number of specialists expected to correctly select the LARS score issues, if they picked randomly, was determined according to hypergeometric distribution. The number of specialists who actually chose the correct issues was calculated and compared with the expected number, using the $\chi^2$ test.

On the basis of our experience with LARS, we hypothesised that, in general, specialists would not be very good at judging what patients find the most bothersome, but should perform at least better than random.

**Exercise 2**

For each of the 11 non-zero score response options, the mean and distribution of the scores assigned by the specialists were calculated and compared with the original patient-derived score, using the one-sample Wilcoxon signed-rank test.

Our hypothesis was that specialists would underestimate the impact of clustering (defined as having to open bowels again within 1 h of the last bowel opening).

**Comparison between subgroups of specialists**

Where appropriate, the results were compared between three subgroups of specialists: colorectal surgeons who deal with functional bowel disorders on a regular basis, colorectal surgeons who do not and radiation oncologists. We hypothesised that the results of surgeons who treat functional disorders would best approximate patient perception, whereas the results of oncologists would least approximate patient perception.

Using the independent samples Kruskal-Wallis test, the number of correct issues chosen was compared in Exercise 1, and the score value assigned was compared in Exercise 2.

All the statistical tests were conducted in IBM SPSS Statistics V.21. A p value of <0.01 was deemed statistically significant.

**RESULTS**

**Participating specialists**

A total of 61 specialists were invited to take part in the study, and 58 (95%) participated. Of the three who did not participate, one was not eligible because he had previously seen the LARS score. The other two were
eligible, but could not take part in the internet teleconferencing session due to time commitments.

The 58 participating specialists comprised 45 (78%) colorectal surgeons and 13 (22%) radiation oncologists. Of the 45 surgeons, 33 (73%) stated that they deal with functional bowel disorders on a regular basis and 12 (27%) stated to the contrary. The majority of the specialists practiced in Europe (52/58, 90%), while the remainder practiced in North America (4/58, 7%) and Asia (2/58, 3%).

**Exercise 1**

The frequency of selection of each of the 17 issues, as compared with the expected frequency of being chosen at random, is displayed in figure 2. Four of the five LARS score issues, namely urgency, clustering, incontinence for liquid stool and frequency of bowel movements (number of daily bowel movements), had the highest frequencies of selection, which were also clearly higher than the random frequency. However, the remaining LARS score issue of incontinence for flatus had a low frequency of selection that was markedly lower than random.

Among issues that are not included in the LARS score, soiling had a high frequency of selection that was discernibly higher than random.

Table 1 shows the number of specialists correctly selecting the LARS score issues, as compared with the expected number if they picked at random. The specialists performed superior to random, with a significantly lower number choosing zero and one correct issue, and a significantly higher number choosing three correct issues. All 58 specialists picked at least one correct issue, but only one (2%) selected all the five issues correctly.

Across all the participants, the median number of correct issues chosen was two of the five (mean 2.4, range 1–5). There was little variation in the number of correct issues selected between the subgroups (p=0.20).

**DISCUSSION**

This study has demonstrated that in general, rectal cancer specialists do not have a very thorough understanding of which bowel dysfunction symptoms truly matter to the patient after sphincter-preserving treatment, nor how these symptoms affect the patient’s QOL, despite LARS being a prevalent and troublesome syndrome. Although the specialists performed better than random, there was considerable discrepancy between the specialist’s perspective and patient experience. Few specialists recognise the importance of incontinence for flatus for the patient. Moreover, specialists tend to overestimate the impact of incontinence for liquid stool and frequent bowel movements, while underestimating the impact of urgency and clustering. Contrary to the hypothesised, no difference was found between the subgroups of specialists, which suggests that even clinicians who routinely deal with functional bowel disorders are not fully aware of the scope and impact of LARS. The fact that the participating specialists are highly regarded on May 11, 2022 by guest. Protected by copyright. http://bmjopen.bmj.com/ BMJ Open: first published as 10.1136/bmjopen-2013-003374 on 21 January 2014. Downloaded from http://bmjopen.bmj.com/ on May 11, 2022 by guest. Protected by copyright.
international experts on the treatment of rectal cancer further highlights the magnitude of the problem.

The LARS score is built on the collective viewpoint of 961 patients. It was formulated based on the experience of half of this cohort, and has been tested against QOL and clinical parameters on the other half of the cohort. It has a high sensitivity and specificity for identifying patients with majorly compromised QOL.\(^\text{11}\) It is also able to show differences between certain patient subgroups in ways that are consistent with clinical rationale.\(^\text{11}\) Therefore, the LARS score is a robust measure of the patient’s perspective of LARS, and its use is the main strength of this study, as it underlies the validity of the results. On the other hand, the generalisability of the results could be limited by the sample of specialists recruited, since it is confined to five particular European colorectal conferences. However, given that the specialists are highly regarded international experts on the treatment of rectal cancer, it is unlikely that another or a larger specialist sample would generate results leading to different conclusions.

Numerous studies have previously reported the discrepancy between the clinician’s judgement of patient perception and the patient’s actual view or experience.\(^\text{14-25}\) These studies were conducted in the areas of symptom severity and QOL in urinary conditions; adverse effects of antipsychotic medications; QOL, anxiety, and depression in patients with cancer; disease activity, health status, functioning and outcomes in rheumatic diseases. The patient sample sizes in these studies were mostly smaller than our current study, and the doctor samples were largely poorly defined or quantified, unlike our study, which gives a clear description of the specialist sample. Furthermore, the doctors involved in these studies were the treating clinician of the participating patients, and not necessarily recognised experts in the field, as in our study. Validated questionnaires were used in several of the studies.\(^\text{14, 16, 20, 21}\) Our current study is the first to document the incongruity between the doctor’s and the patient’s perspective regarding bowel dysfunction following rectal cancer treatment.

Not only is the specialist’s knowledge of LARS crucial in the proper identification, assessment and management of the syndrome, it also underlies the specialist’s ability to provide pertinent information to the patient prior to treatment. A recent population-based study showed that neoadjuvant therapy (short-course radiotherapy or long-course chemoradiotherapy) increased the risk of Major LARS by 2.5-fold.\(^\text{24}\) Even though radiation oncologists do not usually follow patients up after rectal cancer therapy, they should advise about the potential adverse effects that are the most concerning for the patient. Similarly, colorectal surgeons should also adequately inform patients before surgery, as well as review and attend to bothersome symptoms at follow-up. This study indicates that there is a need for improved clinician education of LARS. Moreover, the study supports the use of the LARS score in routine clinical practice. When assessing what is relevant to the patient and how the patient is affected, the patient’s own rating should always be the gold-standard.\(^\text{25 26}\) The LARS score enables a patient-centred and standardised evaluation of LARS, which can guide the clinician in appropriately addressing the syndrome.\(^\text{27}\)

---

**Table 1** Observed and expected number of specialists selecting the correct issues

<table>
<thead>
<tr>
<th>Correct issues chosen</th>
<th>Expected number of specialists</th>
<th>Observed number of specialists</th>
<th>p Value of difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>7</td>
<td>0</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>1</td>
<td>23</td>
<td>9</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>23</td>
<td>0.70</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>21</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>4</td>
<td>1</td>
<td>4</td>
<td>0.17</td>
</tr>
<tr>
<td>5</td>
<td>0.009</td>
<td>1</td>
<td>0.32</td>
</tr>
</tbody>
</table>

---

**Figure 3** Specialist and patient score of each response option.
incorporate the LARS score in routine follow-up after sphincter-preserving rectal cancer treatment in Denmark, Netherlands, and Sweden.

Prior to the development of the LARS score, several instruments for faecal incontinence had been used in various studies to measure incontinence in LARS patients, including the Wexner Incontinence Score, the Rockwood Faecal Incontinence Severity Index and the St Marks’ Faecal Incontinence Grading Score.28–36 This may have influenced the clinician to think that LARS is predominantly about faecal incontinence. In addition, the sizeable number of incontinence instruments available and the large volume of incontinence research to date indicate that faecal incontinence has been the main focus of bowel dysfunction in general. The emphasis on faecal incontinence may at least partially account for the substantial overestimation of the impact of incontinence for liquid stool and frequent bowel movements (which is closely related to incontinence) found in our study. The same may also explain the finding that soiling (which is not included in the LARS score) was chosen more frequently than incontinence for flatus (which is part of the LARS score). It is important to remember that LARS is a complex, multifaceted syndrome that involves more than just faecal incontinence and frequency. Clustering and urgency, which are the other aspects of the syndrome, should not be overlooked, especially when these are the symptoms that patients find the most bothersome, as revealed through the development of the LARS score (as shown in figure 1, clustering and urgency are the highest scoring questions in the LARS score).

We hope that this novel study serves to raise the awareness and improve the understanding of LARS among clinicians, and prompts a closer communication with the patient throughout the treatment and follow-up process. Further work is required to ensure the alignment of doctor and patient perception of LARS.

Acknowledgements The authors would like to thank Michael Varth for advice on statistical analysis, and the International Low Anterior Resection Syndrome Group for assistance with data collection. The following are members of the International Low Anterior Resection Syndrome Group: Herand Abcarian (USA), Richard Adams (UK), Matthew Albert (USA), Cornelius Baeten (the Netherlands), David Bartolo (UK), Willem Belman (the Netherlands), Sabine Bieri (Switzerland), Tom Cecil (UK), Andre D’Hoore (Belgium), Elcio de Graaf (the Netherlands), Ignace de Hingh (the Netherlands), Hans de Wilt (the Netherlands), Rainer Fietkau (Germany), Abe Fikrat (France), Alois Fürst (Germany), Andrew Gaya (UK), Elisabeth Geijsen (the Netherlands), Michael Gerhards (the Netherlands), Bengt Gilmius (Sweden), Rob Glynne-Jones (UK), Karin Haustermans (Belgium), Richard (Bill) Heald (UK), Friedrich Herbst (Austria), Franc Hetzer (Switzerland), Werner Hohenberger (Germany), Torbjörn Holm (Sweden), Christoph Isbert (Germany), Lene Iversen (Denmark), Seon-Hahn Kim (South Korea), Sergio Larach (USA), Paul-Antoine Lehou (France), Jacob Lindegaard (Denmark), Hendrik Martijn (the Netherlands), Anna Martling (Sweden), Christoph Maurer (Switzerland), Brendan Moran (UK), Ronan O’Connell (Ireland), Michael (Mike) Parker (UK), Carlo Ratto (Italy), Eric Rullier (France), Reinhard Ruppert (Germany), Harm Rutten (the Netherlands), Thomas Schiedeck (Germany), Karl Sandenaa (Norway), Sigmar Stelzner (Germany), Angelo Stuto (Italy), Kenichi Sugihara (Japan), Diana Tait (UK), Emile Tan (UK), Pieter Tanis (the Netherlands), Paris Tekiss (UK), Vincenzo Valentini (Italy), Kurt Van Der Speeten (Belgium), Steven Wexner (USA), Joachim Widder (the Netherlands), Theo Wiggers (the Netherlands), Albert Wolthus (Belgium), Evangelos Xynos (Greece).

Contributors SL and TY-TC participated in the study conception and design. SL, TY-TC, KJE and all members of the International Low Anterior Resection Syndrome Group participated in acquisition of the data. TY-TC, SL and Michael Varth participated in analysis and interpretation of the data. TY-TC participated in drafting of the article. SL and KJE participated in critical revision of the article for important intellectual content. SL, KJE and TY-TC participated in the final approval of the published version. SL is the guarantor.

Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All the authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/

REFERENCES


